

# Richard Horuk

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11372282/publications.pdf>

Version: 2024-02-01

110  
papers

12,675  
citations

38660

50  
h-index

38300

95  
g-index

114  
all docs

114  
docs citations

114  
times ranked

10382  
citing authors

#	ARTICLE	IF	CITATIONS
1	Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection. <i>Cell</i> , 1996, 86, 367-377.	13.5	2,964
2	Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor. <i>Cell</i> , 1993, 72, 415-425.	13.5	798
3	International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors. <i>Pharmacological Reviews</i> , 2014, 66, 1-79.	7.1	735
4	CD4-independent association between HIV-1 gp120 and CXCR4: functional chemokine receptors are expressed in human neurons. <i>Current Biology</i> , 1997, 7, 112-121.	1.8	486
5	Neuronal apoptosis induced by HIV-1 gp120 and the chemokine SDF-1 $\alpha$ is mediated by the chemokine receptor CXCR4. <i>Current Biology</i> , 1998, 8, 595-598.	1.8	428
6	Chemokine receptors. <i>Cytokine and Growth Factor Reviews</i> , 2001, 12, 313-335.	3.2	372
7	Chemokine and chemokine receptor expression in the central nervous system. <i>Journal of NeuroVirology</i> , 1999, 5, 13-26.	1.0	274
8	Chemokine/Chemokine Receptor Nomenclature. <i>Journal of Interferon and Cytokine Research</i> , 2002, 22, 1067-1068.	0.5	273
9	Chemokine receptor antagonists: overcoming developmental hurdles. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 23-33.	21.5	267
10	Regulation of Human Chemokine Receptors CXCR4. <i>Journal of Biological Chemistry</i> , 1997, 272, 28726-28731.	1.6	260
11	CCR1+/CCR5+ Mononuclear Phagocytes Accumulate in the Central Nervous System of Patients with Multiple Sclerosis. <i>American Journal of Pathology</i> , 2001, 159, 1701-1710.	1.9	238
12	Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and TH1-like/CD45RO+T cells. <i>Blood</i> , 2001, 97, 1144-1146.	0.6	228
13	I want a new drug: G-protein-coupled receptors in drug development. <i>Drug Discovery Today</i> , 2006, 11, 481-493.	3.2	204
14	Chemokines, chemokine receptors and small-molecule antagonists: recent developments. <i>Trends in Pharmacological Sciences</i> , 2002, 23, 459-467.	4.0	201
15	An Orphan Seven-Transmembrane Domain Receptor Expressed Widely in the Brain Functions as a Coreceptor for Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus. <i>Journal of Virology</i> , 1998, 72, 7934-7940.	1.5	183
16	Identification and Characterization of a Potent, Selective, and Orally Active Antagonist of the CC Chemokine Receptor-1. <i>Journal of Biological Chemistry</i> , 2000, 275, 19000-19008.	1.6	177
17	The interleukin-8-receptor family: from chemokines to malaria. <i>Trends in Immunology</i> , 1994, 15, 169-174.	7.5	171
18	A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. <i>Journal of Clinical Investigation</i> , 2002, 109, 251-259.	3.9	165

#	ARTICLE	IF	CITATIONS
19	The CC Chemokine I-309 Inhibits CCR8-dependent Infection by Diverse HIV-1 Strains. <i>Journal of Biological Chemistry</i> , 1998, 273, 386-391.	1.6	159
20	Molecular properties of the chemokine receptor family. <i>Trends in Pharmacological Sciences</i> , 1994, 15, 159-165.	4.0	156
21	MIP-1 $\alpha$ utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. <i>Experimental Hematology</i> , 2005, 33, 272-278.	0.2	148
22	CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. <i>Kidney International</i> , 2004, 66, 2264-2278.	2.6	129
23	Genetic Subtype-Independent Inhibition of Human Immunodeficiency Virus Type 1 Replication by CC and CXC Chemokines. <i>Journal of Virology</i> , 1998, 72, 396-404.	1.5	128
24	Chemokine Receptor CCR1 But Not CCR5 Mediates Leukocyte Recruitment and Subsequent Renal Fibrosis after Unilateral Ureteral Obstruction. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 337-347.	3.0	124
25	Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor. <i>Journal of Biological Chemistry</i> , 1998, 273, 15687-15692.	1.6	123
26	A Non-peptide Functional Antagonist of the CCR1 Chemokine Receptor Is Effective in Rat Heart Transplant Rejection. <i>Journal of Biological Chemistry</i> , 2001, 276, 4199-4204.	1.6	121
27	Human Immunodeficiency Virus-1 Entry Into Purified Blood Dendritic Cells Through CC and CXC Chemokine Coreceptors. <i>Blood</i> , 1997, 90, 1379-1386.	0.6	119
28	The clinical potential of chemokine receptor antagonists. , 2005, 107, 44-58.		107
29	Late Onset of Treatment with a Chemokine Receptor CCR1 Antagonist Prevents Progression of Lupus Nephritis in MRL-Fas(lpr) Mice. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 1504-1513.	3.0	105
30	Chemokine receptor antagonists: Part 1. <i>Expert Opinion on Therapeutic Patents</i> , 2009, 19, 39-58.	2.4	105
31	Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model. <i>Clinical and Experimental Metastasis</i> , 2006, 23, 291-300.	1.7	103
32	The human erythrocyte inflammatory peptide (chemokine) receptor. Biochemical characterization, solubilization, and development of a binding assay for the soluble receptor. <i>Biochemistry</i> , 1993, 32, 5733-5738.	1.2	99
33	A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. <i>Journal of Clinical Investigation</i> , 2002, 109, 251-259.	3.9	99
34	Delayed Chemokine Receptor 1 Blockade Prolongs Survival in Collagen 4A3 $\alpha$ -Deficient Mice with Alport Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 977-985.	3.0	94
35	Chemokine Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 9363-9392.	2.9	92
36	Chemokine receptor antagonists: part 2. <i>Expert Opinion on Therapeutic Patents</i> , 2009, 19, 199-221.	2.4	91

#	ARTICLE	IF	CITATIONS
37	Predictions of CCR1 Chemokine Receptor Structure and BX 471 Antagonist Binding Followed by Experimental Validation. <i>Journal of Biological Chemistry</i> , 2006, 281, 27613-27620.	1.6	88
38	Leukocytes Induce Epithelial to Mesenchymal Transition after Unilateral Ureteral Obstruction in Neonatal Mice. <i>American Journal of Pathology</i> , 2007, 171, 861-871.	1.9	87
39	The Promiscuous Chemokine Binding Profile of the Duffy Antigen/Receptor for Chemokines Is Primarily Localized to Sequences in the Amino-terminal Domain. <i>Journal of Biological Chemistry</i> , 1995, 270, 26239-26245.	1.6	86
40	The Solution Structure of Melanoma Growth Stimulating Activity. <i>Journal of Molecular Biology</i> , 1994, 242, 252-270.	2.0	83
41	CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model. <i>Immunology Letters</i> , 2001, 76, 193-201.	1.1	80
42	Chemokine Receptor CCR1 Regulates Inflammatory Cell Infiltration after Renal Ischemia-Reperfusion Injury. <i>Journal of Immunology</i> , 2008, 181, 8670-8676.	0.4	79
43	Chemokine receptors and HIV-1: the fusion of two major research fields. <i>Trends in Immunology</i> , 1999, 20, 89-94.	7.5	78
44	The biology and biochemistry of the glucose transporter. <i>BBA - Biomembranes</i> , 1988, 947, 571-590.	7.9	77
45	Why CCR2 and CCR5 Blockade Failed and Why CCR1 Blockade Might Still Be Effective in the Treatment of Rheumatoid Arthritis. <i>PLoS ONE</i> , 2011, 6, e21772.	1.1	72
46	Chemokines beyond inflammation. <i>Nature</i> , 1998, 393, 524-525.	13.7	67
47	Discovery of Novel Non-Peptide CCR1 Receptor Antagonists. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 4680-4694.	2.9	59
48	CC Chemokine Receptor 8 in the Central Nervous System Is Associated with Phagocytic Macrophages. <i>American Journal of Pathology</i> , 2003, 162, 427-438.	1.9	59
49	Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 467-483.	2.5	59
50	Chemokine Receptor Antagonists. , 2000, 20, 155-168.		56
51	CCR5 Deficiency Aggravates Crescentic Glomerulonephritis in Mice. <i>Journal of Immunology</i> , 2008, 181, 6546-6556.	0.4	55
52	A Mutant of Melanoma Growth Stimulating Activity Does Not Activate Neutrophils but Blocks Erythrocyte Invasion by Malaria. <i>Journal of Biological Chemistry</i> , 1995, 270, 11472-11476.	1.6	53
53	Elucidation of Binding Sites of Dual Antagonists in the Human Chemokine Receptors CCR2 and CCR5. <i>Molecular Pharmacology</i> , 2009, 75, 1325-1336.	1.0	52
54	Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor. <i>European Journal of Pharmacology</i> , 2000, 389, 41-49.	1.7	50

#	ARTICLE	IF	CITATIONS
55	CCR1 is an early and specific marker of Alzheimer's disease. <i>Annals of Neurology</i> , 2003, 54, 638-646.	2.8	50
56	The Duffy Antigen Receptor for Chemokines DARC/ACKR1. <i>Frontiers in Immunology</i> , 2015, 6, 279.	2.2	49
57	CXCR4 on human endothelial cells can serve as both a mediator of biological responses and as a receptor for HIV-2. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2000, 1500, 227-240.	1.8	48
58	The Chemokine, CCL3, and Its Receptor, CCR1, Mediate Thoracic Radiation-Induced Pulmonary Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 45, 127-135.	1.4	47
59	Development and evaluation of pharmacological agents targeting chemokine receptors. <i>Methods</i> , 2003, 29, 369-375.	1.9	41
60	CCR1 antagonists in clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 785-796.	1.9	40
61	Expression and Coreceptor Function of APJ for Primate Immunodeficiency Viruses. <i>Virology</i> , 2000, 276, 435-444.	1.1	39
62	Promiscuous drugs as therapeutics for chemokine receptors. <i>Expert Reviews in Molecular Medicine</i> , 2009, 11, e1.	1.6	38
63	Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3. <i>British Journal of Pharmacology</i> , 2012, 166, 912-923.	2.7	38
64	BX471: A CCR1 Antagonist with Anti-Inflammatory Activity in Man. <i>Mini-Reviews in Medicinal Chemistry</i> , 2005, 5, 791-804.	1.1	36
65	Structure Function Differences in Nonpeptide CCR1 Antagonists for Human and Mouse CCR1. <i>Journal of Immunology</i> , 2003, 170, 1910-1916.	0.4	29
66	Identification and Characterization of a Potent, Selective Nonpeptide Agonist of the CC Chemokine Receptor CCR8. <i>Molecular Pharmacology</i> , 2006, 69, 309-316.	1.0	29
67	Expression, purification and in vitro functional reconstitution of the chemokine receptor CCR1. <i>Protein Expression and Purification</i> , 2009, 66, 73-81.	0.6	28
68	A CCR1 antagonist prevents the development of experimental autoimmune myocarditis in association with T cell inactivation. <i>Journal of Molecular and Cellular Cardiology</i> , 2006, 40, 853-861.	0.9	25
69	Treatment with BX471, a CC chemokine receptor 1 antagonist, attenuates systemic inflammatory response during sepsis. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 292, G1173-G1180.	1.6	25
70	Cell-Autonomous Regulation of Neutrophil Migration by the D6 Chemokine Decoy Receptor. <i>Journal of Immunology</i> , 2013, 190, 6450-6456.	0.4	25
71	Identification and characterization of the rat adipocyte glucose transporter by photoaffinity crosslinking. <i>FEBS Letters</i> , 1983, 164, 261-266.	1.3	23
72	Treatment With BX471, a Nonpeptide CCR1 Antagonist, Protects Mice Against Acute Pancreatitis-Associated Lung Injury by Modulating Neutrophil Recruitment. <i>Pancreas</i> , 2007, 34, 233-241.	0.5	22

#	ARTICLE	IF	CITATIONS
73	Chapter 13 Modeling Small Moleculeâ€“Compound Binding to Gâ€“Proteinâ€“Coupled Receptors. Methods in Enzymology, 2009, 460, 263-288.	0.4	22
74	Chemokines: Molecular double agents. Current Biology, 1996, 6, 1581-1582.	1.8	21
75	[10] Iodination of chemokines for use in receptor binding analysis. Methods in Enzymology, 1997, 288, 134-148.	0.4	20
76	Small Molecule Antagonists of Chemokine Receptors - is Promiscuity a Virtue?. Current Topics in Medicinal Chemistry, 2010, 10, 1351-1358.	1.0	20
77	Rapid and effective transfer of integral membrane proteins from isoelectric focusing gels to nitrocellulose membranes. Analytical Biochemistry, 1986, 157, 123-128.	1.1	19
78	[3] Chemokine receptors in developing human brain. Methods in Enzymology, 1997, 288, 27-38.	0.4	17
79	Noncompetitive, Chemokine-mediated Inhibition of Basic Fibroblast Growth Factor-induced Endothelial Cell Proliferation. Journal of Biological Chemistry, 1998, 273, 7911-7919.	1.6	15
80	An improved and simplified apparatus for protein extraction and concentration from gel slices, using moving boundary electrophoresis. Electrophoresis, 1983, 4, 335-337.	1.3	13
81	Partial purification and characterization of the glucagon receptor. FEBS Letters, 1983, 155, 213-217.	1.3	13
82	CXCR 3 antagonist VUF 10085 binds to an intrahelical site distinct from that of the broad spectrum antagonist TAK â€“779. British Journal of Pharmacology, 2015, 172, 1822-1833.	2.7	13
83	Post-binding events in insulin action. Molecular and Cellular Endocrinology, 1985, 42, 1-20.	1.6	12
84	Chemokines. Scientific World Journal, The, 2007, 7, 224-232.	0.8	12
85	Gene activation therapy: from the BLV model to HAM/TSP patients. Frontiers in Bioscience - Elite, 2009, 1, 205.	0.9	12
86	Chapter 9 The Duffy Antigen Receptor for Chemokines. Methods in Enzymology, 2009, 461, 191-206.	0.4	10
87	Human Immunodeficiency Virus-1 Entry Into Purified Blood Dendritic Cells Through CC and CXC Chemokine Coreceptors. Blood, 1997, 90, 1379-1386.	0.6	8
88	Photoaffinity labeling of the glucagon receptor with a new glucagon analog. FEBS Journal, 1984, 141, 63-67.	0.2	7
89	Post binding events in insulin action. Diabetes/metabolism Reviews, 1985, 1, 59-97.	0.2	6
90	Duffy antigen inhibitors: useful therapeutics for malaria?. Trends in Parasitology, 2010, 26, 329-333.	1.5	6

#	ARTICLE	IF	CITATIONS
91	Review Biologicals & Immunologicals; The Chemokine Receptor Family. Expert Opinion on Therapeutic Patents, 1995, 5, 1185-1200.	2.4	5
92	Chemokine Receptor Antagonists: From the Bench to the Clinic. , 2006, , 371-402.		5
93	Expression, purification, and characterization of Escherichia coli-derived recombinant human melanoma growth stimulating activity. Methods in Enzymology, 1997, 287, 3-12.	0.4	3
94	Possible mechanism for the generation of the HIV-1-resistant form of the CCR5 $\Delta$ 32 mutant chemokine receptor. Current Biology, 1997, 7, R529-R530.	1.8	3
95	<i>In vitro</i> screening for chemokine antagonists. Expert Opinion on Drug Discovery, 2009, 4, 1017-1034.	2.5	3
96	Alanine scan mutagenesis of chemokines. Methods in Enzymology, 1997, 287, 59-69.	0.4	2
97	[20] Adenylate cyclase assays to measure chemokine receptor function. Methods in Enzymology, 1997, 288, 326-339.	0.4	2
98	Controlling leukocyte trafficking in disease. , 2006, , 181-196.		1
99	Chemokines and Chemokine Receptors in the Brain. , 1999, , 295-312.		1
100	Pharmaceutical Targeting of Chemokine Receptors. , 2007, , 371-390.		1
101	4-Azetidinyl-1-heteroatom linked cyclohexane antagonists of CCR2: patent evaluation. Expert Opinion on Therapeutic Patents, 2011, 21, 1275-1280.	2.4	0
102	Chemokine Receptors in Allergy, Inflammation, and Infectious Disease. Topics in Medicinal Chemistry, 2014, , 1-39.	0.4	0
103	CXCR4 Chemokine Receptor. , 2007, , 1-10.		0
104	Chemokine receptor CCR1. The AFCS-nature Molecule Pages, 0, , .	0.2	0
105	Glucagon Receptors and Their Functions. , 1985, , 251-279.		0
106	Chemokine Receptor CCR1. , 2016, , 1-9.		0
107	CCR1. , 2016, , 260-268.		0
108	Chemokine Receptor CCR1. , 2018, , 1065-1074.		0

#	ARTICLE	IF	CITATIONS
109	The Duffy Antigen Receptor for Chemokines. , 2020, , 125-144.		0
110	Chemokine Receptors. , 2021, , 444-450.		0